Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer

Excerpt:

“Pfizer Inc. (NYSE:PFE) today announced Phase 2 data showing that its investigational, dual-mechanism poly ADP ribose polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline (inherited) BRCA1/2-positive (gBRCA+) advanced breast cancer. Results from the Phase 2 ABRAZO trial were presented during an oral session at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


AstraZeneca’s Lynparza Slows Spread of Inherited Breast Cancer

Excerpt:

AstraZeneca Plc showed that its drug Lynparza slowed progression of a devastating, inherited form of breast cancer that typically strikes younger women, potentially opening up a new market for a pill originally approved to treat ovarian tumors.

“A study of 302 women, dubbed OlympiAD, found that those getting the drug were 42 percent less likely to see their cancer spread than those given conventional chemotherapy, according to results presented at the American Society of Clinical Oncology meeting in Chicago. Women taking Lynparza had their disease progress after about seven months, compared with 4.2 months of median progression-free survival for those on chemotherapy.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.